OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
95014056

Englewood Lab Inc

Personal ProductsVerified

Englewood Lab Inc maintains a strong liquidity position, with a current ratio of 3.55 and cash and equivalents amounting to $25,129,940. The company's liquidity is further supported by a low debt-to-equity ratio of 0.16, indicating a conservative capital structure. In terms of profitability, the company demonstrates a return on equity of 15.21% and a return on assets of 11.03%. These figures suggest that the company is effectively utilizing its equity and assets to generate returns, outperforming the typical benchmarks for the personal products industry. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no significant geographic diversification reported, which could pose a concentration risk if the primary market experiences economic downturns. Looking at the growth trajectory, the company's recent financial performance shows a revenue of $152,431,010. While the company has a positive operating cash flow of $15,606,710, the capital expenditure of -$4,698,180 indicates a reduction in investment in physical assets, which may affect long-term growth. The risk assessment for Englewood Lab Inc indicates a low liquidity risk and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is minimal given the equal number of basic and diluted shares outstanding. Recent events, as reflected in the financial data, show a strong performance in terms of net income of $17,447,730 and a gross profit of $42,204,860. The company's financial health is further supported by a high return on equity and a strong operating income of $26,274,560.

30-day price · 950140-1050.00 (-8.4%)
Low$11150.00High$12880.00Close$11450.00As of14 May, 00:00 UTC
Profile
CompanyEnglewood Lab Inc
Ticker950140.KQ
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Products
AI analysis

Business. Englewood Lab Inc provides personal products and services, primarily operating in the consumer non-cyclicals sector.

Classification. The company is classified under the industry of Personal Products within the Personal & Household Products & Services business sector, with a classification confidence of 0.92.

Englewood Lab Inc maintains a strong liquidity position, with a current ratio of 3.55 and cash and equivalents amounting to $25,129,940. The company's liquidity is further supported by a low debt-to-equity ratio of 0.16, indicating a conservative capital structure. In terms of profitability, the company demonstrates a return on equity of 15.21% and a return on assets of 11.03%. These figures suggest that the company is effectively utilizing its equity and assets to generate returns, outperforming the typical benchmarks for the personal products industry. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no significant geographic diversification reported, which could pose a concentration risk if the primary market experiences economic downturns. Looking at the growth trajectory, the company's recent financial performance shows a revenue of $152,431,010. While the company has a positive operating cash flow of $15,606,710, the capital expenditure of -$4,698,180 indicates a reduction in investment in physical assets, which may affect long-term growth. The risk assessment for Englewood Lab Inc indicates a low liquidity risk and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is minimal given the equal number of basic and diluted shares outstanding. Recent events, as reflected in the financial data, show a strong performance in terms of net income of $17,447,730 and a gross profit of $42,204,860. The company's financial health is further supported by a high return on equity and a strong operating income of $26,274,560.
Key takeaways
  • Englewood Lab Inc has a strong liquidity position with a current ratio of 3.55 and a low debt-to-equity ratio of 0.16.
  • The company's profitability is robust, with a return on equity of 15.21% and a return on assets of 11.03%.
  • Revenue is concentrated in a single business segment, which could pose a concentration risk.
  • The company has a low liquidity and dilution risk, with no immediate filing-based flags detected.
  • Recent financial performance indicates a strong operating cash flow and a positive net income.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable due to consistent cost management and pricing strategies.
  • **rd_outlook_rationale**: Research and development expenditures are not disclosed, but the company's focus on personal products suggests ongoing innovation efforts.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$152.4M
Gross profit$42.2M
Operating income$26.3M
Net income$17.4M
R&D
SG&A
D&A
SBC
Operating cash flow$15.6M
CapEx-$4.7M
Free cash flow$15.0M
Total assets$158.2M
Total liabilities$43.5M
Total equity$114.7M
Cash & equivalents$25.1M
Long-term debt$18.1M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$114.7M
Net cash$7.0M
Current ratio3.5
Debt/Equity0.2
ROA11.0%
ROE15.2%
Cash conversion89.0%
CapEx/Revenue-3.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Personal Products · cohort 185 companies
Metric950140Activity
Op margin17.2%6.0% medp25 0.5% · p75 12.6%top quartile
Net margin11.4%5.2% medp25 0.5% · p75 10.9%top quartile
Gross margin27.7%43.2% medp25 26.0% · p75 61.0%below median
R&D / revenue1.8% medp25 1.8% · p75 1.8%
CapEx / revenue-3.1%-3.0% medp25 -5.5% · p75 -1.3%below median
Debt / equity16.0%13.3% medp25 2.5% · p75 55.2%above median
Observations
IR observations
Last actual EPS981.15 USD
Last actual revenue182,052,000,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-14 00:46 UTC#3a4893b0
Market quoteclose USD 11380.00 · shares 0.02B diluted
no public URL
2026-05-14 00:48 UTC#3b84ebf7
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 05:03 UTCJob: fecb97e1